Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art

Cancer Cell Int. 2023 Aug 5;23(1):157. doi: 10.1186/s12935-023-02996-6.

Abstract

Chimeric antigen receptor natural killer cells (CAR-NK) promote off-the-shelf cellular therapy for solid tumors and malignancy.However,, the development of CAR-NK is due to their immune surveillance uncertainty and cytotoxicity challenge was restricted. Natural killer cell-derived exosome (NK-Exo) combine crucial targeted cellular therapies of NK cell therapies with unique non-toxic Exo as a self-origin shuttle against cancer immunotherapy. This review study covers cytokines, adoptive (autologous and allogenic) NK immunotherapy, stimulatory and regulatory functions, and cell-free derivatives from NK cells. The future path of NK-Exo cytotoxicity and anti-tumor activity with considering non-caspase-independent/dependent apoptosis and Fas/FasL pathway in cancer immunotherapy. Finally, the significance and implication of NK-Exo therapeutics through combination therapy and the development of emerging approaches for the purification and delivery NK-Exo to severe immune and tumor cells and tissues were discussed in detail.

Keywords: CAR-NK; Cancer immunotherapy; Exosomes; Fas/FasL pathway; Immunostimulation; NK-derived Exosomes; Natural killer cell.

Publication types

  • Review